Wire · opportunities
Is Johnson & Johnson (JNJ) Resetting Its Device Business With Two Fresh Moves?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
Johnson & Johnson received CE Marking in Europe for its ACUVUE OASYS MAX reusable contact lenses aimed at digital device users, and agreed to divest its Laminar left atrial appendage closure program assets to Jaguar LAA, shifting development responsibility.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You need to reassess which Medtech niches Johnson & Johnson is exiting and entering this quarter because their capital is shifting away from left atrial appendage closure and doubling down on digital-device-friendly eye care. That reallocation opens space for you to capture the orphaned cardiovascular customers or innovate alongside J&J's new focus.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics